Small molecule · developed by Novartis Pharmaceuticals
Ganaplacide (KLU156, GNF-156, KAF156) is an oral antimalarial compound given as a sachet formulation together with lumefantrine (LUM-SDF) and combined with cipargamin (KAE609). It is being studied in uncomplicated Plasmodium falciparum malaria.
Summary written with AI from the sources listed at the end of this page.
Uncomplicated Plasmodium Falciparum Malaria
Updated Oct 25, 2026. Something wrong or missing? Report it on the NVS page.
See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVS catalysts and pipeline →